Diabetic macular edema remains an important cause of vision ... techniques. The Diabetic Retinopathy Clinical Research (DRCR) Network, which includes over 199 participating sites, is currently ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

Diabetic macular edema can result in low vision or vision loss. Early treatment can help preserve vision longer. Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood ...

Adjusted estimates show a 2.5-fold higher risk of MI and a 2-fold higher risk of CVA in patients with DME compared with diabetic patients ... 362.53 (cystoid macular edema) plus 250.xx (diabetes ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...